Management of intermittent claudication with pentoxifylline: Meta-analysis of randomized controlled trials

CMAJ. Canadian Medical Association Journal

Volumn 155, Issue 8, 1996, Pages 1053-1059

  Hood, Sheila C ^a   Moher, David ^b   Barber, Graeme G ^c  

^a STATISTICS CANADA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PENTOXIFYLLINE; PERIPHERAL VASODILATING AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; INTERMITTENT CLAUDICATION; MAJOR CLINICAL STUDY; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREADMILL; WALKING;

EID: 0029914108     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Rudofsky G, Haussler KF, Kunkel HP, et al. Intravenous treatment of chronic peripheral occlusive arterial disease: a double-blind, placebo-controlled, randomized, multicenter trial of pentoxifylline. Angiology 1989;40:639-49.
2. Compendium of pharmaceuticals and specialities. Toronto: Canadian Pharmaceutical Association, 1996:1502-3.
3. Rossner M, Muller K. On the assessment of the efficacy of pentoxifylline. J Med 1987;18:1-15.
4. Cameron HA, Waller PC, Ramsey LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985. Br J Clin Pharmacol 1988;26:569-76.
5. Radack K, Wyderski RJ. Conservative management of intermittent claudication. Ann Intern Med 1990;113:135-46.
6. Ernst E. Pentoxifylline for intermittent claudication: a critical review. Angiology 1994;45:339-45.
7. Sacks HS, Berrier J, Reitman D, et al. Meta-analysis of randomized controlled trials. N Engl J Med 1987;316:450-5.
8. Oxman AD, Guyatt GH. Guidelines tor reading literature reviews. Can Med Assoc J 1988;138:697-703.
9. Lindegarde F, Jelnes R, Bjorkman H, et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation 1989;80:1549-56.
10. Ernst E, Kollar L, Resch KL. Does pentoxifylline prolong the walking distance in exercised claudicants? A placebo-controlled double-blind trial. Angiology 1992;43:121-5.
11. Porter JM, Baur GM. Pharmacologic treatment of intermittent claudication. Surgery 1982;92:966-71.
12. Berglund B, Eklund B. Reproducibility of treadmill exercise in patients with intermittent claudication. Clin Physiol 1981;1:253-6.
13. De Felice M, Gallo P, Masotti G. Current therapy of peripheral arterial disease - the non-surgical approach. Angiology 1990;41:1-11.
14. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
15. Thomson GJL, Thomson S, Todd AS, et al. Combined intravenous and oral pentoxifylline in the treatment of peripheral vascular disease. Int Angiol 1990;9:266-70.
16. Reilly DT, Quinton DN, Barrie WW. A controlled trial of pentoxifylline (Trental 400) in intermittent claudication: clinical, haemostatic and rheological effects. N Z Med J 1987;100:445-7.
17. Porter JM, Cutler BC, Lee BV, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982;104:66-72.
18. Donaldson DR, Hall TJ, Kester RC. Does pentoxifylline (Trental) have a place in the treatment of intermittent claudication? Curr Med Res Opin 1984;9:35-40.
19. Roekaerts F, Deleers L. Trental 400 in the treatment of intermittent claudication: results of a long-term, placebo-controlled administration. Angiology 1984;35:396-406.
20. Strano A, Davi G, Avellone G, et al. Double-blind crossover study of the clinical efficacy and the hemmorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 1984;35:459-66.
21. Bollinger A, Frei C. Double-blind study of pentoxifylline against placebo in patients with intermittent claudication. Pharmatherapeutica 1977;1:557-62.
22. Di Perri T, Guerrini M. Placebo controlled double blind study with pentoxifylline of walking performance in patients with intermittent claudication. Angiology 1983;34:40-5.
23. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine. Monogr Epidemiol Biostat 1994;24:115-30.
24. Kellner H. Zur Behandlung chronischer aterieller Durchblutungs-storungen. Munch Med Wochenschr 1976;188:1399-402.
25. Schubotz R. Double-blind trial of pentoxifylline in diabetics with peripheral vascular disorders. Pharmatherapeutica 1976;1:172-9.
26. Volker D. Berhanlung von arteriopathien mit Trental 400. Med Welt 1978;29:1244-7.
27. Johnson WC, Sentissi IM, Baldwin D, et al. Treatment of claudication with pentoxifylline: Are benefits related to improvements in viscosity? J Vasc Surg 1987;6:211-6.
28. Thomas JH, Swannack CJ, McAnaw M, et al. Determinants of response to pentoxifylline therapy in patients with intermittent claudication. Am J Surg 1987;154:663-5.
29. Green RM, McNamara J. The effects of pentoxifylline on patients with intermittent claudication. J Vasc Surg 1988;7:356-62.
30. Chopra HK, Chopra KL, Aggarwal KK, et al. Pentoxifylline - a new drug for the treatment of intermittent claudication. Indian Heart J 1989;41:127-33.
31. Crowder JF, Cohn JB, Savitsky JP, et al. Efficacy and safety of pentoxifylline in geriatric patients with intermittent claudication. Angiology 1989;40:795-802.
32. AbuRhama AF, Woodruff BA. Effect and limitations of pentoxifylline therapy in various stages of peripheral vascular disease of the lower extremity. Am J Surg 1990;160:266-70.
33. Perhoniemi V, Salmenkivi K, Sundberg S, et al. Effects of flunarizine and pentoxifylline on walking distance and blood rheology in claudication. Angiology 1984;35:366-72.
34. Chacon-Quevedo A, Eguaras MG, Calleja F. Comparative evaluation of pentoxifylline, buflomedil, and nifedipine in the treatment ot intermittent claudication of the lower limbs. Angiology 1994;45:647-53.
35. Scheffler P, de la Hamette D, Gross J, et al. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. Circulation 1994;90:818-22.
36. Feine-Haake G. Zur Objektivierung der therapeutischen Wirksamkeit von Trental 400 - Doppelblinversuch bei geriatrischen Patienten mit Durchblutungsstorungen. Fortschr Med 1977;95:46-51.
37. Kieswetter H, Blume J, Jung F, et al. Gehtraining und medikamentose Therapic bei der peripheren arteriellen Verschuskrankheit. Randomisierte, prospektive, placebo-kontrollierte Doppelblindstudie. Dtsch Med Wochenschr 1987;112:873-8.
38. Reith T, Cutler BC, Lee BY, et al. Pentoxifylline in the treatment of intermittent claudication of the lower limbs. Angiology 1984;35:389-95.
39. Gallus AS, Gleadow F, Dupont P. Intermittent claudication: a double-blind crossover trial of pentoxifylline. Aust N Z J Med 1985;15:402-9.
40. Dettori AG, Pini M, Moratti A, et al. Acenocoumerol and pentoxifylline in intermittent claudication: a controlled clinical study. Angiology 1989;40:237-48.
41. Reich T, Gillings D. Effects of pentoxifylline on severe intermittent claudication. Angiology 1987;38:651-6.
42. Spitzer S, Bach R, Schieffer H. Walk training und drug treatment in patients with peripheral arterial occlusive disease Stage II: A review. Int Angiol 1992;11:204-10.
43. Begg CC, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996; 276:637-9.
44. Stegarchis A, Sheingold S, Luce B, et al. Medical can and cost outcomes after pentoxifylline treatment for peripheral arterial disease. Arch Intern Med 1992;152:1220-24.